Research
Neural
Patients prescribed semaglutide or tirzepatide had an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) with a hazard ratio of 1.76.
Clinicians should monitor patients on semaglutide or tirzepatide for signs of NAION.
StrongSupportsmedium confidence
During the 2-year follow-up, there were 35 patients (0.04%) with NAION in the semaglutide or tirzepatide group and 19 patients (0.02%) with NAION in the matched comparison group (hazard ratio, 1.76 [95% CI, 1.01-3.07]).
Why this rating
Based on a large cohort study design.
Source
Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes
Lindsey Wang et al. · JAMA Network Open · 2025
cohort · n=159398Cited 25×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →